Alison Moore
2020
In 2020, Alison Moore earned a total compensation of $2.5M as Chief Technical Officer at Allogene Therapeutics, a 21% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $220,000 |
|---|---|
| Option Awards | $1,262,643 |
| Salary | $440,000 |
| Stock Awards | $561,176 |
| Total | $2,483,819 |
Moore received $1.3M in option awards, accounting for 51% of the total pay in 2020.
Moore also received $220K in non-equity incentive plan, $440K in salary and $561.2K in stock awards.
Rankings
In 2020, Alison Moore's compensation ranked 4,578th out of 13,090 executives tracked by ExecPay. In other words, Moore earned more than 65.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,578 out of 13,090 | 65th |
Division Manufacturing | 1,854 out of 5,621 | 67th |
Major group Chemicals And Allied Products | 722 out of 2,254 | 68th |
Industry group Drugs | 619 out of 1,954 | 68th |
Industry Biological Products, Except Diagnostic Substances | 145 out of 411 | 65th |
Source: SEC filing on April 22, 2021.
Moore's colleagues
We found four more compensation records of executives who worked with Alison Moore at Allogene Therapeutics in 2020.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019